Adenosine is the metabolic common pathway of rapid antidepressant action: The coffee paradox

(Press-News.org) NEW YORK, New York, USA, 11 November 2025 -- Perhaps the most intriguing implication of recent breakthrough research lies in an unexpected connection: the most rigorous mechanistic dissection of rapid antidepressant action identifies adenosine as the critical mediator, yet adenosine receptors are the primary target of caffeine, the world's most widely consumed psychoactive substance.

A commentary published today in Brain Medicine by Drs. Julio Licinio and Ma-Li Wong explores this striking convergence. Is this merely coincidence, or does it reveal something fundamental about why humans have gravitated toward caffeine consumption across cultures and millennia?

A Mechanistic Mystery Solved For over two decades, ketamine's rapid antidepressant effects puzzled researchers. The electrically induced intervention of electroconvulsive therapy worked when nothing else did. Both treatments helped, but the mechanistic thread connecting these varied interventions remained elusive.

Now, Professor Min-Min Luo and colleagues' landmark Nature study (10.1038/s41586-025-09755-9) has revealed the answer: adenosine signaling. Using cutting-edge genetically encoded adenosine sensors, Luo's team demonstrated that both ketamine and ECT trigger adenosine surges in mood-regulatory brain circuits. When they blocked adenosine receptors, the therapeutic effects vanished. When they activated these receptors, they replicated the antidepressant response.

The Clinical Question Luo's Discovery Raises But Luo's discovery raises a critical question that the original research does not address: What about caffeine?

"This is where clinical practice meets mechanistic insight," explains Dr. Licinio. "Caffeine blocks the same adenosine receptors that Luo's team showed are essential for ketamine and ECT to work. We are potentially looking at a major treatment interference that nobody has been systematically tracking."

Understanding Coffee's Contradictory Effects The epidemiological protection that chronic coffee drinking confers against depression may represent an inadvertent form of adenosinergic modulation operating at population scale. Yet the same mechanism that provides tonic benefit might interfere with phasic therapeutic surges during acute treatment.

Licinio and Wong's commentary synthesizes Luo's findings with decades of clinical observations about caffeine and depression. "Patients routinely show up for ketamine infusions or ECT having consumed their morning coffee," notes Dr. Wong. "Based on Luo's mechanistic data, we need to be asking whether that is sabotaging their treatment."

Beyond Caffeine: New Therapeutic Possibilities The implications extend beyond caffeine. Luo's team identified adenosine as a tractable therapeutic target, demonstrating that acute intermittent hypoxia, controlled reductions in oxygen levels, produces antidepressant effects through the same adenosine pathway. Unlike ketamine's potential for abuse or ECT's cognitive side effects, intermittent hypoxia offers a potentially scalable, non-invasive intervention.

"What is most intriguing is that Luo showed all three interventions, ketamine, ECT, and intermittent hypoxia, converge on adenosine," says Dr. Licinio. "This unified framework helps us understand not just how these treatments work, but how lifestyle factors like coffee consumption might modulate their effectiveness."

The Coffee Paradox Demands Resolution The commentary identifies urgent clinical questions requiring carefully designed studies: Do regular coffee drinkers show altered responses to ketamine or electroconvulsive therapy? Does pre-treatment caffeine washout enhance therapeutic outcomes? Can we develop dosing strategies that preserve the protective effects of chronic consumption while optimizing acute treatment responses?

"The convergence of the world's most prevalent psychoactive drug with the mechanistic lynchpin of our most effective rapid antidepressants is unlikely to be accidental," observes Dr. Licinio. "Understanding this intersection may illuminate both the widespread appeal of caffeine and the optimization of adenosine-targeted therapeutics."

From Mechanism to Clinical Strategy Luo's identification of adenosine as the pivotal mediator provides the mechanistic foundation. Licinio and Wong's analysis translates that discovery into actionable clinical questions. Together, they provide a framework for understanding how disparate interventions achieve rapid antidepressant effects and potentially why some patients do not respond as expected.

This synthesis of cutting-edge neuroscience with clinical pragmatism exemplifies how mechanistic discoveries reshape therapeutic strategy. As Luo's team notes, adenosine signaling represents a "tractable target for scalable, noninvasive therapeutics in major depressive disorder." Licinio and Wong's commentary begins charting the path from that target to optimized treatment.

Sources

 

The Commentary in Brain Medicine titled "Adenosine as the Metabolic Common Path of Rapid Antidepressant Action: The Coffee Paradox," is freely available via Open Access on 11 November 2025 in Brain Medicine at the following hyperlink: https://doi.org/10.61373/bm025c.0134.

The Nature study by Yue and colleagues led by Professor Min-Min Luo titled “Adenosine signalling drives antidepressant actions of ketamine and ECT," is available at: https://doi.org/10.1038/s41586-025-09755-9.

 

About Brain Medicine: Brain Medicine (ISSN: 2997-2639, online and 2997-2647, print) is a peer-reviewed medical research journal published by Genomic Press, New York. Brain Medicine is a new home for the cross-disciplinary pathway from innovation in fundamental neuroscience to translational initiatives in brain medicine. The journal's scope includes the underlying science, causes, outcomes, treatments, and societal impact of brain disorders, across all clinical disciplines and their interface.

 

Visit the Genomic Press Virtual Library: https://issues.genomicpress.com/bookcase/gtvov/

 

Our full website is at: https://genomicpress.com/

END